Cargando…
Predictors of Mortality in Light Chain Cardiac Amyloidosis with Heart Failure
Cardiac involvement in systemic amyloidosis (AL) occurs in ~50% of all AL patients. However once symptomatic heart failure develops, therapeutic options are limited thereby conferring a poor overall prognosis. The median survival is <6 months when AL patients are untreated for the underlying plas...
Autores principales: | Tahir, Usman A., Doros, Gheorghe, Kim, John S., Connors, Lawreen H., Seldin, David C., Sam, Flora |
---|---|
Formato: | Online Artículo Texto |
Lenguaje: | English |
Publicado: |
Nature Publishing Group UK
2019
|
Materias: | |
Acceso en línea: | https://www.ncbi.nlm.nih.gov/pmc/articles/PMC6561903/ https://www.ncbi.nlm.nih.gov/pubmed/31189919 http://dx.doi.org/10.1038/s41598-019-44912-x |
Ejemplares similares
-
Circulating Matrix Metalloproteinases and Tissue Inhibitors of Metalloproteinases in Cardiac Amyloidosis
por: Tanaka, Komei, et al.
Publicado: (2013) -
Correlation Between 24-Hour Urine Protein and Random Urine Protein-Creatinine Ratio in Amyloid Light-Chain Amyloidosis
por: Mendelson, Lisa, et al.
Publicado: (2022) -
Race/ethnicity in systemic AL amyloidosis: perspectives on disease and outcome disparities
por: Staron, Andrew, et al.
Publicado: (2020) -
Features of atrial fibrillation in wild‐type transthyretin cardiac amyloidosis: a systematic review and clinical experience
por: Mints, Yuliya Y., et al.
Publicado: (2018) -
Marked progress in AL amyloidosis survival: a 40-year longitudinal natural history study
por: Staron, Andrew, et al.
Publicado: (2021)